Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical outcomes of transcatheter aortic valve implantation in patients younger than 70 years rejected for surgery: the AMTRAC registry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Percutaneous left atrial appendage closure in a surgically ligated left atrial appendage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Computed Tomography-Based Selection of Transseptal Puncture Site for Percutaneous Left Atrial Appendage Closure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cusp overlap technique during Valve-in-Valve TAVI using the novel Navitor transcatheter heart valve

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Membranous septum morphology predicting the risk of conduction abnormalities after transcatheter aortic valve implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Does Subclinical Leaflet Thrombosis Impact the Durability of Bioprosthetic Aortic Valves?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Percutaneous left atrial appendage closure in a surgically ligated left atrial appendage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Microcirculatory Function in Nonhypertrophic and Hypertrophic Myocardium in Patients With Aortic Valve Stenosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Guy Witberg
  • Uri Landes
  • Pablo Codner
  • Marco Barbanti
  • Roberto Valvo
  • Ole De Backer
  • Joris F W Ooms
  • Angela McInerney
  • Giulia Masiero
  • Paul Werner
  • Xavier Armario
  • Claudia Fiorina
  • Dabit Arzamendi
  • Sandra Santos-Martinez
  • Jose A Baz
  • Klemen Steblovnik
  • Victor Mauri
  • Matti Adam
  • Ilan Merdler
  • Manuel Hein
  • Philipp Ruile
  • Marco Russo
  • Francesco Musumeci
  • Alexander Sedaghat
  • Atsushi Sugiura
  • Carmelo Grasso
  • Luca Branca
  • Rodrigo Estevez-Loureiro
  • Ignacio J Amat-Santos
  • Darren Mylotte
  • Martin Andreas
  • Matjaz Bunc
  • Giuseppe Tarantini
  • Luis Nombela-Franco
  • Lars Søndergaard
  • Nicolas M Van Mieghem
  • Ariel Finkelstein
  • Ran Kornowski
Vis graf over relationer

BACKGROUND: The mean age of transcatheter aortic valve implantation (TAVI) patients is steadily decreasing.

AIMS: The aim of the study was to describe the characteristics, the indications for and the outcomes of TAVI in patients <70 years old.

METHODS: All patients undergoing TAVI (n=8,626) from the 18 participating centres between January 2007 and June 2020 were stratified by age (</>70). For patients <70, the indications for TAVI were extracted from Heart Team discussions and the baseline characteristics and mortality were compared between the two groups.

RESULTS: Overall, 640 (7.4%) patients were <70 (9.1% during 2018-2020, p<0.001); the mean age was 65.0±2.3 years. The younger patients were more often male, with bicuspid valves or needing valve-in-valve procedures. They had a higher prevalence of lung disease and diabetes. In 80.7% of cases, the Heart Team estimated an increased surgical risk and TAVI was selected, reflected by an STS score >4% in 20.4%. Five-year mortality was similar (29.4 vs 29.8%, HR 0.95, p=0.432) in the <70 and >70 groups. In the <70 group, mortality was higher for those referred for TAVI due to an increased surgical risk compared to those referred for other reasons (31.6 vs 24.5%, HR 1.23, p=0.021). Mortality was similar regardless of the STS stratum in patients judged by the Heart Team to be at increased surgical risk (32.6 vs 30.4%, HR 0.98, p=0.715).

CONCLUSIONS: Use of TAVI in patients <70 is becoming more frequent. The main reason for choosing TAVI is due to an increased surgical risk not adequately represented by the STS score. The outcomes for these patients are similar to those for older TAVI patients. Dedicated trials of TAVI/SAVR in younger patients are needed to guide decisions concerning expansion of TAVI indications. ((ClinicalTrials.gov: NCT04031274).

OriginalsprogEngelsk
TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Vol/bind17
Udgave nummer16
Sider (fra-til)1289-1297
Antal sider9
ISSN1774-024X
DOI
StatusUdgivet - 18 mar. 2022

ID: 72637453